Severe, Reversible Pulmonary Hypertension in a Patient With Monoclonal Gammopathy and Features of Dermatomyositis
- Sitaxsentan more effective than bosentan as PAH therapy. // Formulary;Jan2006, Vol. 41 Issue 1, p46
The article examines the effectiveness of sitaxsentan compared with bosentan for the treatment of pulmonary arterial hypertension (PAH). Sitaxsentan is a highly selective endothelin-A receptor antagonist. It may be beneficial for patients with PAH due to connective tissue disease. It is also...
- Inhaled epoprostenol therapy for pulmonary hypertension: Improves oxygenation index more consistently in neonates than in older children. Brown, Anna T.; Gillespie, Jennifer V.; Miquel-Verges, Franscesca; Holmes, Kathryn; Ravekes, William; Spevak, Philip; Brady, Ken; Blaine Easley, R.; Christopher Golden, W.; McNamara, LeAnn; Veltri, Michael A.; Lehmann, Christoph U.; McMillan, Kristen Nelson; Schwartz, Jamie M.; Romer, Lewis H. // Pulmonary Circulation;2012, Vol. 2 Issue 1, p61
The purpose of this study was to determine the efficacy of inhaled epoprostenol for treatment of acute pulmonary hypertension (PH) in pediatric patients and to formulate a plan for a prospective, randomized study of pulmonary vasodilator therapy in this population. Inhaled epoprostenol is an...
- Frequency of pleural effusions in patients with pulmonary arterial hypertension associated with connective tissue diseases. Luo, Y. F.; Robbins, I. M. // International Journal of Advances in Rheumatology;2011, Vol. 9 Issue 4, p146
Pleural effusions are common in patients with pulmonary hypertension associated 'with connective tissue diseases, and are frequendy associated with right-sided heart failure.
- Pharmacotherapy of Chronic Pulmonary Arterial Hypertension: Value and Limitations Part II: Secondary Pulmonary Hypertension. Alpert, Martin A.; Concannon, Milton D.; Mukerji, Basanti; Mukerji, Vaskar // Angiology;Sep1994, Vol. 45 Issue 9, p755
Part I of this review discussed pharmacotherapy of primary pulmonary hypertension (PHT). Part II describes the value and limitations of oxygen and vasodilator therapy of secondary PHT, focusing on patients with PHT associated with selected connective tissue disease and chronic nonthrombotic...
- Paradoxical Effect of Prostacyclin Infusion in a Patient with Primary Pulmonary Hypertension. Younger, Jared R.; Lui, Charles Y. // Angiology;May/Jun2004, Vol. 55 Issue 3, p341
Prostacyclin treatment successfully delays the need for lung transplantation in many patients with progressive primary pulmonary hypertension by vasodilating pulmonary arteries. However, the treatment of pulmonary hypertension with prostacyclin may cause a paradoxical increase in pulmonary...
- Epidemiology. // Current Medical Literature: Pulmonary Hypertension;2012, Vol. 3 Issue 1, p17
The article reviews several studies concerning the epidemiology of pulmonary arterial hypertension (PAH). It highlights the study that indicates the commonality of pleural effusions connective tissue disease (CTD)-associated PAH. It also examines the study that claims that iron deficiency is a...
- Foreword. // Current Medical Literature: Pulmonary Hypertension;2012, Vol. 3 Issue 1, pIV
A foreword to the "Current Medical Literature: Pulmonary Hypertension" is presented.
- Empowered Patient Online Toolkit. // Advances in Pulmonary Hypertension;Summer2012, Vol. 11 Issue 2, p104
The article recommends the comprehensive Empowered Patient Toolkit for patients with pulmonary hypertension by Pulmonary Hypertension Association (PHA).
- First inhaled prostacyclin for pulmonary hypertension. LoBuono, Charlotte // Drug Topics;2/21/2005, Vol. 149 Issue 4, p13
Pulmonary arterial hypertension (PAH) affects thousands of people in the U.S., yet only few patients have been diagnosed and are receiving an approved treatment. This article reports the U.S. Food and Drug Administration's approval of the first inhaled prostacyclin for the treatment of PAH....